header logo image


Page 6«..5678..»

Archive for the ‘Nano medicine’ Category

The Europe exosome diagnostic and therapeutic market is projected to reach US$ 12,524.24 thousand in 2019 to US$ 104,694.72 thousand by 2027 -…

Friday, October 2nd, 2020

New York, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Exosome Diagnostic and Therapeutic Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Application ; Product ; End User, and Country" - https://www.reportlinker.com/p05974359/?utm_source=GNW

Exosome is an emerging industry with a huge potential.Applications of exosomes are expanding rapidly in the areas of disease diagnosis and treatment as well as pharmaceuticals.

Exosomes are nanovesicles and act as a vehicle to deliver therapies to cells of the body.In the future, exosomes can be used as potential biomarkers and in the field of personalized medicine.

Interest in exosome research has increased dramatically in recent years, driving the growth of the exosome diagnostic and therapeutic market in the UK.New exosome therapeutics companies are rapidly entering the marketplace.

The investment flow has also increased to support such innovative therapeutic companies, further boosting the growth of the market. For example, in 2016, ReNeuron Group plc, a leading UK-based stem cell therapy development company, was awarded about US$ 2.6 million grant from Innovate UK to advance its emerging exosome nanomedicine platform.In terms of application, the diagnostics application segment accounted for a larger share of the Europe exosome diagnostic and therapeutic market. Its growth is attributed to an increasing adoption of exosome-based instruments and kits for diagnosis of chronic conditions. Additionally, exosome-based diagnostic products offer benefits such as accuracy, lower processing time, and better ergonomics; these are likely to drive the growth of diagnostic application segment in the Europe exosome diagnostic and therapeutic marketIn 2019, the instrument segment held a considerable share of the for exosome diagnostic and therapeutic market, by the product.This segment is also predicted to dominate the market by 2027 owing to higher demand for diagnostics instruments.

However, the software segment is anticipated to witness growth at a significant rate during the forecast period.A few major primary and secondary sources for the exosome diagnostic and therapeutic market included in the report are Instrument, US Food and Drug Administration, and World Health Organization, among others.Read the full report: https://www.reportlinker.com/p05974359/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Link:
The Europe exosome diagnostic and therapeutic market is projected to reach US$ 12,524.24 thousand in 2019 to US$ 104,694.72 thousand by 2027 -...

Read More...

Nanorobotics Market to Witness Huge Growth by 2024 | Bruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments – The Daily Chronicle

Friday, October 2nd, 2020

Global Nanorobotics Market report study covers the breakdown data with production, consumption, revenue and market share by regions, type and applications. Historical breakdown data from 2015 to 2019 and forecast to 2024

The comprehensive numerical analyses of Global NanoroboticsMarket Research Report 20202024 is a historical overview and in-depth study on the current & future market of the Nanorobotics industry. he report focuses on the historical and current market trends to predict the course of the global Nanorobotics market in the upcoming years. The report identifies opportunities, drivers, and major challenges faced by market players. The report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments. The research further provides par excellence futuristic estimations for various vital factors including market size, share, net profit, sales, revenue, and growth rate. The market competition by top manufacturers/players, with sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including market:Bruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments, EV Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik. This report provides in-depth analysis of the Nanorobotics market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (20202024).

Request for Sample Report @https://www.indexmarketsresearch.com/report/global-nanorobotics-market/431987/#requestforsample

Global major manufacturers of the market are also assessed with their information such as company profiles, product picture and specification, capacity, production, price, cost, market trend, revenue, and contact data. The research provides details regarding each product like the cost breakup, import/export scheme, manufacturing volume, price, gross, growth ratio, investments, and contribution to the global Nanorobotics revenue. The facts and data are represented in the Nanorobotics Market report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better. We have provided a detailed study on the critical dynamics of the global Nanorobotics market, which include the market influence and market effect factors, drivers, challenges, restraints, trends, and prospects. Global Nanorobotics Industry Market Research Report is providing exclusive vital statistics, information, data, trends and competitive landscape details. The research study also includes other types of analysis such as qualitative and quantitative. The document also comprises of a detailed assessment of the regional scope of the market alongside its regulatory outlook. Additionally, the report provides with a detailed SWOT analysis while elaborating market driving factors. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. Nanorobotics market report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

The Nanorobotics market report includes the overall and comprehensive study of the Nanorobotics market with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the Nanorobotics industry and provides data for making strategies to increase the market growth and effectiveness. The Market report lists the most important competitors and provides the insights strategic industry Analysis of the key factors influencing the market. This report will help you to establish a landscape of industrial development and characteristics of the Nanorobotics market. The Global Nanorobotics market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. It also provides statistical data on all the recent developments in the market. It also comprises a basic overview and revenue and strategic analysis under the company profile section. Nanorobotics market analysis is provided for the international markets including development trends, competitive landscape analysis, investment plan, business strategy, opportunity, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.

Regional Analysis:This section of the report contains detailed information on the market in different regions. Each region offers a different market size because each state has different government policies and other factors. The regions included in the report areNorth America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and SouthAfrica)Information about the different regions helps the reader to better understand the global Nanorobotics market.

Most important types of the market covered in this report are:Nanomanipulator, Bio-Nanorobotics, Magnetically Guided, Bacteria-Based

Most widely used downstream fields of market covered in this report are:Nanomedicine, Biomedical, Mechanical

Research objectives: The points that are discussed within the Nanorobotics Market report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc. Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements. The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. To analyze the Nanorobotics with respect to individual growth trends, future prospects, and their contribution to the total market. Focuses on the key global Nanorobotics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To project the consumption of Nanorobotics submarkets, with respect to key regions (along with their respective key countries). To strategically profile the key players and comprehensively analyze their growth strategies. The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail. The Nanorobotics market report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions Answered: What is the size and CAGR of the global World Nanorobotics Market? Which are the leading segments of the global World Nanorobotics Market? What are the key driving factors of the most profitable regional market? What is the nature of competition in the global World Nanorobotics Market? How will the global Home Appliance market advance in the coming years? What are the main strategies adopted in the global World Nanorobotics Market? What are sales, revenue, and price analysis by types and applications of Nanorobotics market? What are sales, revenue, and price analysis by regions of Nanorobotics industry?

The Essential Content Covered in the Global Nanorobotics Market Report :* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

Read Detailed Index Report @https://www.indexmarketsresearch.com/report/global-nanorobotics-market/431987/

The Nanorobotics market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies. This report is comprehensive numerical analyses of the Nanorobotics industry and provides data for making strategies to increase the market growth and success. The Report also estimates the market size, Price, Revenue, Gross Margin and Market Share, cost structure and growth rate for decision making. A detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, threats, and global markets including progress trends, competitive landscape analysis, and key regions expansion status.

At last, This report investigates the Nanorobotics market in the global market, presents the latest business analysis including market scope, product situation, technology growth, environmental distribution, business situation, and chain structure. industrial. Nanorobotics Market Report Shares Important Data on Impact Factors, Advertising Drivers, Challenges, the report gives the inside and out examination of Nanorobotics Market took after by above components, which are useful for organizations or individual for development of their present business or the individuals who are hoping to enter in Nanorobotics industry.

Request customize If you wish to find more details of the report or want a Customization Please contacts us. You can get a detailed of the entire research here.

Contact Us @[emailprotected]

View post:
Nanorobotics Market to Witness Huge Growth by 2024 | Bruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments - The Daily Chronicle

Read More...

What is Nanoscience? | Outlook and How to Invest | INN – Investing News Network

Thursday, September 24th, 2020

Nanoscience has made an impact on a range of industries. With continuous developments, it will only get more exciting for investors.

Through nanotechnology, nanoscience has undeniably impacteda range of industries, from energy to medicine. In the face of continuous nanotechnology research and development, experts are promising an exciting future for the industry.

The terms nanoscience and nanotechnology have been around for a long time, and its common for them to be used interchangeably. However, its important to note that they are not the same.

According toErasmus Mundus, the European Unions higher education program, nanoscience refers to the study, manipulation and engineering of particles and structures on a nanometer scale. For its part, nanotechnology is described as the design and application of nanoscience.

In simple terms, nanoscience is the study of nanomaterials and properties, while nanotechnology is using these materials and properties to create a new product.

Here the Investing News Network provides a comprehensive look at nanoscience investing and nanomaterials, with an overview of the subjects and where they are headed in the future.

The University of Sydneys Nano Institute describes nanoscience as the study of the structure and function of materials on the nanometer scale.

Nanometers are classified as particles that are roughly the size of about 10 atoms in a row. Under those conditions, light and matter behave in a different way as compared to normal sizes.

These behaviours often defy the classical laws of physics and chemistry and can only be understood using the laws of quantum mechanics, the universitys research page states.

The Institute of Nanoscience of Aragon identifies carbon nanotubes (CNTs) as one example of a component that is designed at the nanoscale level. These structures are stronger than steel at the macroscale level. CNT powders are currently used in diverse commercial products, from rechargeable batteries to automotive parts to water filters.

Scientists, researchers and industry experts are enthusiastic about nanoscience and nanoparticles.

As noted in a study published by Jeffrey C. Grossman, a University of California student, quantum properties come into play at the nanoscale level. In simple terms, at the nanoscale level, a materials optical properties, such as color, can be controlled.

Further, the paper states that the surface-to-volume ratio increases at the nano size, opening up new possibilities for applications in catalysis, filtering, and new composite materials, to name only a few.

In other words, the opening up of surface area, which adds new possibilities, can have drastic effects on industries such as manufacturing. New applications in catalysis can allow manufacturing to be sped up, while new composite materials can add more dimension to an end product.

Nanoscale developments could also lead to increased resources and could play a role in the energy sector by increasing efficiency.

As the Royal Society putsit, the aim of nanoscience and nanotechnologies is to produce new or enhanced nanoscale materials.

Nanomaterials are formed when materials have their properties changed at the nanoscale level. Nanomaterials involve elements that contain at least one nanoscale structure, but there are several subcategories of nanomaterials based on their shape and size.

According to the Royal Society, nanowires, nanotubes and nanoparticles like quantum dots, along with nanocrystalline materials, are said to be nanomaterials.

While these are broader classifications of nanomaterials, each of them has several submaterials. Graphene is one popular submaterial and is an example of a nanoplate.

The Integrated Nano-Science & Commodity Exchange, a self-regulated commodity exchange, includes a wide range of nanomaterials and related commodities and lists more than 1,000 nanomaterials.

The exchange states that its entire product range is in excess of 4,500 products, including CNTs, graphene, graphite, ceramics, drug-delivery nanoparticles, metals, nanowires, micron powders, conductive inks, nano-fertilizers and nano-polymers.

As can be seen, nanoscience and nanotechnology are used in a variety of applications across diverse fields, from energy to manufacturing. The University of Sydneys Nano Institute highlights how nanoscienceimpacts manufacturing, energy and the environment through the continuous development of new nano and quantum materials.

With the advancement of materials science and technology, solutions are being worked on for the health and medicine fields, with nanobots gaining popularity in the medical field.

Similarly, nanomaterials like graphene are having a major impact in the technology field graphene is used for various purposes, including in cooling and in batteries.

According to IndustryARC, the global nanotechnology market is projected to reach US$121.8 billion by 2025, growing at a compound annual growth rate of 14.3 percent between 2020 and 2025.

In the US, the National Nanotechnology Initiative, a US government research and development initiative that involves 20 federal and independent agencies, has received cumulative funding of US$27 billion since 2001 to advance research and development of nanoscale projects.

With growth predicted across multiple areas and industries, and with researchers and institutes working on developing the nanoscience field, investors have a slew of nanotechnology stocks to consider.

One popular investment avenue is via graphene, with companies in the space including Applied Graphene Materials (LSE:AGM,OTC Pink:APGMF) and Haydale Graphene Industries (LSE:HAYD). Meanwhile, nanotech stock options include firms such as NanoViricides (NYSE:NNVC), Nano Dimension (NASDAQ:NNDM) and Sona Nanotech (CSE:SONA).

This is an updated version of an article first published by the Investing News Network in 2019.

Dont forget to follow us @INN_Technology or real time updates!

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

Read more:
What is Nanoscience? | Outlook and How to Invest | INN - Investing News Network

Read More...

Penn lab and startup awarded $667000 NIH grant to improve COVID-19 antibody testing – The Daily Pennsylvanian

Thursday, September 24th, 2020

Bioengineering professor Andrew Tsourkas leads the TITAN Lab. (Photo from Andrew Tsourkas)

The National Institutes of Health awarded a Penn Engineering lab and Penn-based startup $667,000 to improve COVID-19 detection technology.

Led by Bioengineering professor Andrew Tsourkas, the Targeted Imaging Therapeutics and Nanomedicine (Titan) Lab partnered with AlphaThera, a startup located at the Pennovation Center, to improve the ELISA technology, which is widely used to detect COVID-19 infections. ELISA, also known as enzyme-linked immunosorbent assay, is used to detect antibodies, proteins the body makes to fight an infection like COVID-19.

By improving ELISA technology, the Titan lab and AlphaThera will enable faster and more sensitive antibody tests for COVID-19 patients. According to the Centers for Disease Control and Prevention, antibody tests may allow patients to determine if they have previously been infected with COVID-19, but do not detect a current COVID-19 infection.

James Hui, who founded AlphaThera alongside Tsourkas, said the company has been working on reducing the time it takes to complete an ELISA assay in detecting antibodies for COVID-19.

These assays can take anywhere between three hours to six hours, but we can do these ELISA assays about probably half the time if not more," said Hui, who received a Ph.D. in Bioengineering from Penn in 2015 and Doctor of Medicine from the Perelman School of Medicine in 2017.

AlphaThera is responsible for developing the ELISA assays, while Tsourkas lab conducts pre-clinical testing for further development of the technology before testing on human samples. After AlphaThera's assays have been validated with the test samples, the team will begin clinical trials in Ping Wang lab at Penn Medicine on about 80 human samples from both COVID-19 and non-COVID-19 patients, Tsourkas said.

The main benefit for the lab is that it shows a practical application for some basic technology we developed in the lab, Tsourkas said. It's always nice to see something turned into a product and be useful for laboratories beyond our own.

Tsourkas said his lab's research also focuses on improving ELISA's sensitivity to detect antibodies, which will help healthcare workers identify a greater number of patients who were previously infected with the virus.

We have some cool antibody labeling technologies that we think will give us a significant boost in sensitivity and how rapid we can read out whether the patient has those antibodies in their serum, he said.

Their goal is to have the technology's validation studies be completed and for kits to be made available to the public within a year, Tsourkas said.

Vaccines imitate an infection while almost never causing illness, prompting the body to produce antibodies and white blood cells that will remember how to fight the disease in the future. Tsourkas said, therefore, fast antibody tests to determine whether a vaccine has prompted the body to produce antibodies will become more important as vaccine development progresses.

As vaccines are being developed now, we need to check to see whether they're working and to see how much of the population was really exposed [to the virus]," Tsourkas said.

Get our newsletter, Dear Penn, delivered to your inbox every weekday morning.

Tsourkas' research can also be applied to other antibody-detecting assays already on the market to improve their speed and sensitivity, he said.

While AlphaThera has been working to make the technology commercially viable and competitive in the market, Hui said their priority is to ensure the assays' speed and sensitivity in detecting antibodies.

We're not trying to be the first to roll off the market and try to get as much sales as possible, he said. Ultimately, we are a technology company [that is] more interested in developing a better product.

More:
Penn lab and startup awarded $667000 NIH grant to improve COVID-19 antibody testing - The Daily Pennsylvanian

Read More...

Nanomedicine Seen As A Promising Approach For Diagnosis and Treatment Against COVID – PRNewswire

Friday, September 18th, 2020

PLAM BEACH, Fla., Sept. 16, 2020 /PRNewswire/ --The National Institute for Health (NIH) is at the heart of the emerging and rapidly evolving war against the global pandemic. They constantly update the public on the latest information on research for a vaccine and therapies to fight the virus. A recent report from them shone the light on a specific promising therapeutic approach nanomedicine. The NIH said that nanomedicine is a promising approach fordiagnosis, treatment and prophylaxis against COVID-19. They said that: "The COVID-19pandemic caused by the newly emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) puts the world in an unprecedented crisis, leaving behind huge human losses and deep socioeconomic damages. Due to the lack of specific treatment against SARS-CoV-2, effective vaccines and antiviral agents are urgently needed to properly restrain the COVID-19 pandemic. Repositioned drugs such asremdesivir have revealed a promising clinical efficacy against COVID-19. Interestingly, nanomedicine as a promising therapeutic approach could effectively help win the battle between coronaviruses and host cells."Mentioned in today's commentary include: NanoViricides, Inc. (NYSE: NNVC), Immunomedics(NASDAQ: IMMU), Gilead Sciences, Inc. (NASDAQ: GILD), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Novavax, Inc. (NASDAQ: NVAX).

Due to a lack of approved vaccines and specific treatments only preventive measures can currently be applied. Currently, development of an effective vaccine and specific treatment is the main concern for researchers worldwide to fight the current COVID-19 and any future mutations. Understanding the coronaviral genome and the processes of viral replication and pathogenesis will enable researchers to develop specific drugs and vaccines. So researchers are turning to nanomedicine, one of the most important and emerging fields of modern science.

NanoViricides, Inc. (NYSE American: NNVC) Breaking News: NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 NanoViricides, a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials.

The Company has accelerated its drug development program for COVID-19 with the goal of creating the most effective medicine to obtain regulatory approval for emergency use in the COVID-19 pandemic in the shortest timeline feasible, after achieving proof of concept of broad-spectrum anti-coronavirus effectiveness of test candidates. The Company therefore aggressively worked to harness the full power of the nanoviricides nanomedicine platform to achieve these objectives.

A curative treatment for a virus such as SARS-CoV-2 coronavirus would require a multi-faceted attack that shuts down (i) ability of the virus to infect host cells and simultaneously, (ii) ability of the virus to multiply inside the host cells. The nanoviricide platform enables direct multi-point attack on the virus that is designed to disable the virus and its ability to infect new cells. At the same time, a nanoviricide is also capable of carrying payload in its "belly" (inside the micelle) that can be chosen to affect the ability of the virus to replicate. The nanoviricide is designed to protect the payload from metabolism in circulation. Thus, the nanoviricide platform provides an important opportunity to develop a curative treatment against SARS-CoV-2, the cause of COVID-19 spectrum of pathologies.

The clinical candidate the Company has chosen is identified as NV-CoV-1-R. It is made up of a nanoviricide that we have found to possess broad-spectrum anti-coronavirus activity, now identified as NV-CoV-1, and remdesivir encapsulated inside the core of NV-CoV-1. NV-CoV-1 itself is designed to attack the virus particles themselves, and possibly would also attack infected cells that display the virus antigen S-protein, while sparing normal (uninfected) cells that do not display the S-protein. Additionally, remdesivir is widely understood to attack the replication cycle of the virus inside cells. Thus the combined attack enabled by NV-CoV-1-R on the virus could prove to be a cure for the infection and the disease, provided that the necessary dosage level can be attained without undue adverse effects. Human clinical trials will be required to determine the safety and effectiveness of NV-CoV-1-R.

Remdesivir is a well-known antiviral drug (developed by Gilead) that has been approved for emergency use treatment of SARS-CoV-2 infection or COVID-19 in several countries. NV-CoV-1 is a novel agent that is being used as an adjuvant to remdesivir in creating NV-CoV-1-R, to improve the overall effectiveness. It is well known that remdesivir suffers from rapid metabolism in circulation that breaks down the prodrug to its nucleoside form which is not readily phosphorylated. The Company anticipates that encapsulation in NV-CoV-1 may protect remdesivir from this rapid metabolism. If this happens, the effective level and stability of remdesivir in the body would increase. This increase may lead to increased effectiveness if there are no adverse effects. Such increased effectiveness, if found, may also allow reduction in the required dosage of remdesivir in the encapsulated form, i.e. as NV-CoV-1-R. In this sense, NV-CoV-1 can be viewed to act as an adjuvant that enhances the effect of remdesivir, a known antiviral against SARS-CoV-2.

"This is an extremely important milestone for the Company," said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, "We look forward to rapid development of the IND enabling core safety pharmacology studies and, thereafter, human clinical development on an accelerated timeline in these trying times of the pandemic." Read the full press release by going to: http://www.nanoviricides.com/companynews.html

In other biotech news in the markets this week:

Immunomedics(NASDAQ: IMMU) and Gilead Sciences, Inc. (NASDAQ: GILD)recently announcedthat the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the Gilead and Immunomedics Boards of Directors and is anticipated to close during the fourth quarter of 2020.

The agreement will provide Gilead with TrodelvyTM(sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in April for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Immunomedics plans to submit a supplemental Biologics License Application (BLA) to support full approval of Trodelvy in the United States in the fourth quarter of 2020. Immunomedics is also on track to file for regulatory approval in Europe in the first half of 2021.

"This acquisition represents significant progress in Gilead's work to build a strong and diverse oncology portfolio. Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. "We look forward to welcoming the talented Immunomedics team to Gilead so we can continue to advance this important new medicine for the benefit of patients with cancer worldwide."

INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, recently announced that Thermo Fisher Scientific, the world leader in serving science, has signed a letter of intent to manufacture INOVIO's DNA COVID-19 vaccine candidate INO-4800.

Thermo Fisherjoins other contract development and manufacturing organizations in INOVIO's global manufacturing consortium, enabling INOVIO to potentially scale commercial production of INO-4800. With its consortium of third-party manufacturers, INOVIO plans to have 1001million doses of INO-4800 manufactured in 2021, subject to FDA approval of INO-4800 for use as a COVID-19 vaccine.Thermo Fisherplans to manufacture INO-4800 drug substance as well as perform fill and finish of INO-4800 drug product at its commercial facilities in the US. At peak capacity,Thermo Fisherprojects that it could produce at least 100 million doses of INO-4800 annually.

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, recently announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVXCoV2373, Novavax' COVID19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to overtwo billion doses annually, when all planned capacity has been brought online by mid-2021. NVXCoV2373 is a stable, prefusion protein made using Novavax' recombinant protein nanoparticle technology and includes Novavax' proprietary MatrixM adjuvant.

"Today's agreement with Serum Institute enhances Novavax' commitment to equitable global delivery of our COVID-19 vaccine. With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on three continents," said Stanley C. Erck, President and Chief Executive Officer of Novavax. "We continue to work with extraordinary urgency to develop our vaccine, now in Phase 2 clinical trials, and for which we anticipate starting Phase 3 efficacy trials around the world in the coming weeks."

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated twenty five hundred dollars for news coverage of current press release issued by NanoViricides, Inc. by a non-affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:Media Contact email: [emailprotected]+1(561)325-8757

SOURCE FinancialNewsMedia.com

Read more:
Nanomedicine Seen As A Promising Approach For Diagnosis and Treatment Against COVID - PRNewswire

Read More...

Healthcare Nanotechnology Market Insights Competitive Analysis and Future Demand and Revenue Forecast to 2024 | Key Companies: Amgen, Stryker, Teva…

Friday, September 18th, 2020

Healthcare Nanotechnology Market2020-2025 report offerscomprehensive quantitative and qualitative market analysis. This report has been prepared under the continuous observation of the global market situation. This report has been formulated to give our clients the most up to date data and analyses of the Healthcare Nanotechnology Market. The impact on the enterprises and business development, distribution by region and global level is assessed in the report.

Top Companies are covering This Report:-

AmgenStrykerTeva PharmaceuticalsUCBRocheAbbottMerck & CoCelgeneBiogenSanofiLeadiant BiosciencesShireKyowa Hakko KirinGilead SciencesJohnson & Johnson3M CompanyEndo InternationalSmith & NephewPfizerIpsen

The research process involved the study of various factors affecting the industry such as government policy, market environment, competitive landscape, historical data, existing trends in the market, and market risks, opportunities, market barriers and challenges.

Reports Intellect projects Healthcare Nanotechnology Market based on elite players, present, past, and forecast data for the coming years which will act as a profitable guide for all the market competitors. The study includes growth trends, micro- economic and macro-economic indicators in detail and the report has been assessed with the help of PESTEL analysis and other essential analyses operating in the Healthcare Nanotechnology Market. Top-down and bottom-up approaches are used to validate the global Healthcare Nanotechnology market size and estimate the market size for Company, regions segments, product segments and Application.

Get Sample PDF Brochure @https://www.reportsintellect.com/sample-request/905451

The report offers all the essential data for players to secure a position of strength in the market, all while creating a comprehensive action plan. Our analysts here at Reports Intellect have used advanced primary and secondary research techniques to create the most up to date assessment of data on the Healthcare Nanotechnology Market which opens up a plethora of new opportunities to create new strategies to gain leverage over the competition.

Type Coverage:

NanomedicineNano Medical DevicesNano DiagnosisOthersNanomedicine has the highest percentage of revenue by type, with more than 86% in 2019.

Application Coverage:

AnticancerCNS ProductAnti-infectiveOthersAccording to the application, anticancer and CNS products accounted for 17.56% and 22.70% of the market in 2019 respectively.

Market Segment by Regions, regional analysis covers

North America Country (United States, Canada)

South America

Asia Country (China, Japan, India, Korea)

Europe Country (Germany, UK, France, Italy)

Other Country (Middle East, Africa, GCC)

Discount PDF Brochure @https://www.reportsintellect.com/discount-request/905451

Why us:

Reasons to buy:

About Us:-

Contact Us:

Sales@reportsintellect.com

PH + 1-706-996-2486

US Address:

225 Peachtree Street NE,

Suite 400,

Atlanta, GA 30303

Read more here:
Healthcare Nanotechnology Market Insights Competitive Analysis and Future Demand and Revenue Forecast to 2024 | Key Companies: Amgen, Stryker, Teva...

Read More...

Nanoscale Reflective Coating Reverse-Engineered From Fly Eyes – Technology Networks

Friday, September 18th, 2020

The eyes of many insects, including the fruit fly, are covered by a thin and transparent coating made up of tiny protuberances with anti-reflective, anti-adhesive properties. An article published in the journalNaturereveals the secrets of how this nano-coating is made. The authors, from the University of Geneva (UNIGE) and University of Lausanne (UNIL) - together with ETH Zurich (ETHZ) - show that the coating only consists of two ingredients: a protein called retinin and corneal wax. These two components automatically generate the regular network of protuberances by playing the roles of activator and inhibitor, respectively, in a morphogenesis process modelled in the 1950s by Alan Turing. The multi-disciplinary team even succeeded in artificially reproducing the phenomenon by mixing retinin and wax on different kinds of surface. This process, which is very inexpensive and is based on biodegradable materials, was used to obtain nano-coatings with a morphology similar to that of insects, with anti-adhesive and anti-reflective functionalities that could have numerous applications in areas as diverse as contact lenses, medical implants and textiles.

"The nano-coating that covers the surface of the eyes of some insects was discovered in the late 1960s in moths," begins Vladimir Katanaev, a professor in the Department of Cell Physiology and Metabolism in UNIGE's Faculty of Medicine and the study's lead investigator. "It's made up of a dense network of small protrusions about 200 nanometres in diameter and several dozens of nanometres in height. It has the effect of reducing light reflection."

The cornea of an insect without a coating typically reflects about 4% of the incident light, whereas the proportion drops to zero in insects that do have the covering. Although an improvement of 4% may seem small, it is enough of an advantage - especially in dark conditions - to have been selected during evolution. Thanks to its anti-adhesive properties, the coating also provides physical protection against the tiniest dust particles in the air.

Professor Katanaev moved into this research field ten years ago. In 2011, he and his team were the first to discover the nano-coating on the eyes of fruit flies (Drosophila melanogaster). This insect is much more suited to scientific research than moths, in particular because its genome has been completely sequenced.

The Geneva-based researcher has now gathered more evidence to support this hypothesis. Thanks to biochemical analyses and the use of genetic engineering, Professor Katanaev and his colleagues have succeeded in identifying the two components involved in the reaction-diffusion model developed by Turing. This hinges on a protein called retinin and wax produced by several specialised enzymes, two of which have been identified. Retinin plays the role of activator: with its initially unstructured shape, it adopts a globular structure upon contact with the wax and begins to generate the pattern. The wax, on the other hand, plays the role of inhibitor. The powerplay between the two leads to the emergence of the nano-coating.

Initial tests have shown that the coating is resistant to 20 hours of washing in water (it is easily damaged by detergent or scratching, although technological improvements could make it more robust). The anti-reflective properties have already aroused a certain degree of interest among manufacturers of contact lenses, while the anti-adhesive properties could appeal to the producers of medical implants. Indeed, this type of coating could make it possible to control where human cells hook on. Industry already has the techniques needed to obtain this outcome. But they use harsh methods, such as lasers or acids. The Geneva team's solution has the advantage of being inexpensive, benign and totally biodegradable.Reference:

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Nanoscale Reflective Coating Reverse-Engineered From Fly Eyes - Technology Networks

Read More...

R&D Activities to Fast-track the Growth of the Healthcare Nanotechnology (Nanomedicine) Market Between 2015 2021 – The Daily Chronicle

Friday, September 18th, 2020

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Healthcare Nanotechnology (Nanomedicine) market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Healthcare Nanotechnology (Nanomedicine) market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Healthcare Nanotechnology (Nanomedicine) market to assist our clients arrive at beneficial business decisions.

The Healthcare Nanotechnology (Nanomedicine) market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Healthcare Nanotechnology (Nanomedicine) market and the trends that will prevail in this industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

What pointers are covered in the Healthcare Nanotechnology (Nanomedicine) market research study?

The Healthcare Nanotechnology (Nanomedicine) market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Healthcare Nanotechnology (Nanomedicine) market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Healthcare Nanotechnology (Nanomedicine) market report Elucidated with regards to the competitive landscape of the industry:

The competitive expanse of this business has been flawlessly categorized into companies such as

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Healthcare Nanotechnology (Nanomedicine) market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Healthcare Nanotechnology (Nanomedicine) market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Healthcare Nanotechnology (Nanomedicine) market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

Some of the Major Highlights of TOC covers:

See original here:
R&D Activities to Fast-track the Growth of the Healthcare Nanotechnology (Nanomedicine) Market Between 2015 2021 - The Daily Chronicle

Read More...

Medical Biomimetics Market research, Industry Outlook, Current Trends and Forecast by 2025 – The Research Process

Friday, September 18th, 2020

A detailed overview of Medical Biomimetics market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of Medical Biomimetics market in conjunction with the geographical landscape, demand spectrum, remuneration scale, and growth graph of this vertical have also been included in this report.

Increasing rate of organ failure coupled with growing geriatric population base will act as growth impact rendering factors for medical biomimetics market during the forecast timeframe. As per the U.S. Census Bureau?s 2017 National Population Projections, there will be nearly 78 million people aged more than 65 years, while 76.7 million under 18 years of age in the U.S. by 2035, thereby escalating demand for biomimetics products in coming future.

High adoption of western culture, unhealthy diet and physical inactivity has led to rising incidence of cardiovascular diseases, resulting in increased demand for biomimetic cardiovascular products. Numerous applications of biomimetics in healthcare industry including fields such as dentistry, orthopedics, cardiovascular, and ophthalmology should stimulate business growth during the analysis period.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/5768

Medical Biomimetics Market will reach over USD 35 billion by 2025; as per a new research report.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/5768

Orthopedic product segment accounted for more than 30% market share in 2018 and is estimated to witness significant growth during the forecast period owing to growing demand for orthopedic prosthesis and implants. For instance, increasing number of accidents and injuries have escalated the demand for prosthetic limbs. Technological advancements including development of augment bone graft should positively impact segmental growth.

Application segment of medical biomimetics market includes plastic surgery, wound healing, tissue engineering, drug delivery and others including nanomedicine, drug discovery, enzymatic modification and medical engineering. Plastic surgery application segment will witness 6.3% CAGR over the coming years due to wide application of biomimetics in plastic surgery for scaffold formation. It is also used in craniofacial surgery for restoration of facial aesthetics, function and form.

Increasing R&D activities pertaining to development of innovative biomimetic products along with advancements in nanotechnology, tissue engineering utilizing biomimetics technology should positively impact industry expansion. However, high capital investment in R&D along with stringent regulations will hinder industry growth during the forecast timeframe.

Germany medical biomimetics market dominated European region in 2018 and is anticipated to grow at 5.8% during the forecast period. High technological adoption, rising geriatric population prone to suffer from organ failure and increasing incidence of ophthalmology, orthopedic and cardiovascular disorders in the country are driving factors for Germany medical biomimetics market.

Saudi Arabia medical biomimetics market will witness 5.2% CAGR during the forecast timeframe. Growing demand and adoption of cosmetic surgical procedures among women, technological advancements and rising awareness should drive Saudi Arabia medical biomimetics industry during the analysis period. Rising incidence of coronary heart disease coupled with growing uptake of unhealthy habits such as alcohol consumption and tobacco smoking will augment demand for biomimetic products in the region.

Major Highlights from Table of contents are listed below for quick lookup into Medical Biomimetics Market report

Chapter 1. Competitive Landscape

Chapter 2. Company Profiles

Chapter 3. Methodology & Scope

Chapter 4. Executive Summary

Chapter 5. Medical Biomimetics industryInsights

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/5768

Go here to read the rest:
Medical Biomimetics Market research, Industry Outlook, Current Trends and Forecast by 2025 - The Research Process

Read More...

Nanomedicine Market Provides in-depth analysis of the Nanomedicine Industry, with current trends and future estimations to elucidate the investment…

Tuesday, September 15th, 2020

Nanomedicine Market Overview:

Reports and Data has recently published a new research study titled Global Nanomedicine Market that offers accurate insights for the Nanomedicine market formulated with extensive research. The report explores the shifting focus observed in the market to offer the readers data and enable them to capitalize on market development. The report explores the essential industry data and generates a comprehensive document covering key geographies, technology developments, product types, applications, business verticals, sales network and distribution channels, and other key segments.

The report is further furnished with the latest market changes and trends owing to the global COVID-19 crisis. The report explores the impact of the crisis on the market and offers a comprehensive overview of the segments and sub-segments affected by the crisis. The study covers the present and future impact of the pandemic on the overall growth of the industry.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1048

Competitive Landscape:

The global Nanomedicine market is consolidated owing to the existence of domestic and international manufacturers and vendors in the market. The prominent players of the key geographies are undertaking several business initiatives to gain a robust footing in the industry. These strategies include mergers and acquisitions, product launches, joint ventures, collaborations, partnerships, agreements, and government deals. These strategies assist them in carrying out product developments and technological advancements.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Arrowhead Pharmaceuticals Inc. AMAG Pharmaceuticals, Bio-Gate AG, Celgene Corporation, and Johnson & Johnson.

An extensive analysis of the market dynamics, including a study of drivers, constraints, opportunities, risks, limitations, and threats have been studied in the report. The report offers region-centric data and analysis of the micro and macro-economic factors affecting the growth of the overall Nanomedicine market. The report offers a comprehensive assessment of the growth prospects, market trends, revenue generation, product launches, and other strategic business initiatives to assist the readers in formulating smart investment and business strategies.

To read more about the report, visit @ https://www.reportsanddata.com/report-detail/nanomedicine-market

Product Outlook (Revenue, USD Billion; 2017-2027)

Drug Delivery System Outlook (Revenue, USD Billion; 2017-2027)

Application Outlook (Revenue, USD Billion; 2017-2027)

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1048

Key Coverage in the Nanomedicine Market Report:

Thank you for reading our report. Please get in touch with us if you have any queries regarding the report or its customization. Our team will make sure the report is tailored to meet your requirements.

Take a look at other reports from Reports and Data on PR Newswire:

Hydroxycitronellal Market: Hydroxycitronellal Market To Reach USD 192.7 Million By 2027

Sterile Filtration Market: Sterile Filtration Market To Reach USD 8.48 Billion By 2027 | CAGR: 7.7%

Tissue Diagnostics Market: Tissue Diagnostics Market To Reach USD 5.02 Billion By 2027

UV-C Robot Market: UV-C Robot Market to Reach USD 1.46 Billion by 2027

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web:www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail:[emailprotected]

Connect with us:Blogs|LinkedIn|Twitter

Read this article:
Nanomedicine Market Provides in-depth analysis of the Nanomedicine Industry, with current trends and future estimations to elucidate the investment...

Read More...

Tottenham Acquisition I Limited Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with…

Tuesday, September 15th, 2020

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Tottenham Acquisition I Limited (Nasdaq: TOTA, TOTAU, TOTAW, TOTAR) ("Tottenham"), a publicly traded special purpose acquisition company, announced today that its subsidiary, Chelsea Worldwide Inc., has filed with the U.S. Securities and Exchange Commission ("SEC") a registration statement on Form S-4 (the "Registration Statement"), which includes a preliminary proxy statement/consent solicitation statement/prospectus, in connection with its recently-announced proposed business combination with Clene Nanomedicine, Inc. ("Clene"), a clinical-stage biopharmaceutical company developing a potential therapeutic nanocatalyst for the treatment of neurodegenerative diseases in addition to a nanotechnology based-therapy with antiviral applications.

Tottenham's ordinary shares are currently traded on Nasdaq under the symbol "TOTA". In connection with the closing of the transaction, Tottenham intends to change its name to Clene Inc., reincorporate in Delaware (by merging with Chelsea Worldwide Inc.) and remain Nasdaq-listed under a new ticker symbol. Completion of the transaction is subject to approval by Tottenham shareholders, Clene's stockholders, the Registration Statement being declared effective by the SEC, a concurrent closing of private placements and other customary closing conditions.

Chardan is acting as the M&A advisor to Tottenham. LifeSci Capital LLC is acting as the M&A advisor to Clene. Loeb & Loeb LLP is acting as legal advisor to Tottenham. Kirkland & Ellis LLP along with Stoel Rives LLP, Clene's local counsel, are acting as legal advisors to Clene.

About Clene Nanomedicine, Inc.

Clene Nanomedicine, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the development of unique therapeutic candidates for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs.Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based inSalt Lake City, Utahwith R&D and manufacturing operations located inNorth East, Maryland. For more information, please visitwww.clene.com.

About Tottenham Acquisition I Limited

Tottenham Acquisition I Limited is a blank check company formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities. Tottenham's efforts to identify a prospective target business were not limited to a particular industry or geographic region, although the company initially focused on operating businesses in the TMT (Technology, Media, Telecom), education, e-commerce, health-care and consumer goods industries with primary operations inAsia(with an emphasis inChina).

Forward-Looking Statements

This press release contains, and certain oral statements made by representatives of Tottenham, Clene, and their respective affiliates, from time to time may contain, "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Tottenham's and Clene's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Tottenham's and Clene's expectations with respect to future performance and anticipated financial impacts of the business combination, the satisfaction of the closing conditions to the business combination and the timing of the completion of the business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Tottenham or Clene and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed business combination; (2) the outcome of any legal proceedings that may be instituted against Tottenham or Clene following the announcement of the Merger Agreement and the transactions contemplated therein; (3) the inability to complete the business combination, including due to failure to obtain approval of the shareholders of Tottenham or other conditions to closing in the Merger Agreement; (4) delays in obtaining or the inability to obtain necessary regulatory approvals (including approval from regulators, as applicable) required to complete the transactions contemplated by the Merger Agreement; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement or could otherwise cause the transaction to fail to close; (6) the inability to obtain or maintain the listing of the post-acquisition company's ordinary shares on NASDAQ following the business combination; (7) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; (8) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the business combination; (10) changes in applicable laws or regulations; (11) the possibility that Clene or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (12) other risks and uncertainties identified in the Form S-4 filed by Chelsea Worldwide relating to the business combination, including those under "Risk Factors" therein, and in other filings with the Securities and Exchange Commission ("SEC") made by Tottenham and Clene. Tottenham and Clene caution that the foregoing list of factors is neither exclusive nor exhaustive. Tottenham and Clene caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Tottenham or Clene undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Important Information

Chelsea Worldwide Inc., Tottenham, and their respective directors, executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the holders of Tottenham ordinary shares in respect of the proposed transaction described herein. Information about Tottenham's directors and executive officers and their ownership of Tottenham's ordinary shares is set forth in Tottenham's Annual Report on Form 10-K filed with the SEC, as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filing. Other information regarding the interests of the participants in the proxy solicitation are included in the Form S-4 pertaining to the proposed transaction. These documents can be obtained free of charge from the sources indicated below.

In connection with the transaction described herein, Chelsea Worldwide Inc. will file relevant materials with the SEC including a Registration Statement on Form S-4. Promptly after the Registration Statement is declared effective, Tottenham will mail the proxy statement and a proxy card to each shareholder entitled to vote at the extraordinary general meeting relating to the transaction. INVESTORS AND SECURITY HOLDERS OF TOTTENHAM ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTION THAT TOTTENHAM WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT TOTTENHAM, CLENE AND THE TRANSACTION. The proxy statement/consent solicitation/prospectus and other relevant materials in connection with the transaction (when they become available), and any other documents filed by Tottenham with the SEC, may be obtained free of charge at the SEC's website (www.sec.gov).

SOURCE Tottenham Acquisition I Limited

See the article here:
Tottenham Acquisition I Limited Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with...

Read More...

How very tiny technologies are helping tackle the global pandemic – The Next Web

Tuesday, September 15th, 2020

The world-altering coronavirus behind the COVID-19 pandemic is thought to be just 60 nanometres to 120 nanometres in size. This is so mind-bogglingly small that you could fit more than 400 of these virus particles into the width of a single hair on your head. In fact, coronaviruses are so small that we cant see them with normal microscopes and require much fancier electron microscopes to study them. How can we battle a foe so minuscule that we cannot see it?

One solution is to fight tiny with tiny. Nanotechnology relates to any technology that is or contains components that are between 1nm and 100nm in size. Nanomedicine that takes advantage of such tiny technology is used in everything from plasters that contain anti-bacterial nanoparticles of silver to complex diagnostic machines.

Nanotechnology also has an impressive record against viruses and has been used since the late 1880s to separate and identify them. More recently, nanomedicine has been used to develop treatments for flu, Zika, and HIV. And now its joining the fight against the COVID-19 virus, SARS-CoV-2.

If youre suspected of having COVID, swabs from your throat or nose will be taken and tested by reverse transcription polymerase chain reaction (RT-PCR). This method checks if genetic material from the coronavirus is present in the sample.

Despite being highly accurate, the test can take up to three days to produce results, requires high-tech equipment only accessible in a lab, and can only tell if you have an active infection when the test is taken. But antibody tests, which check for the presence of coronavirus antibodies in your blood, can produce results immediately, wherever youre tested.

Antibodies are formed when your body fights back against a virus. They are tiny proteins that search for and destroy invaders by hunting for the chemical markers of germs, called antigens. This means antibody tests can not only tell if you have coronavirus but if you have previously had it.

[Read: Oxfords COVID-19 vaccine is starting to look like a winner]

Antibody tests use nanoparticles of materials such as gold to capture any antibodies from a blood sample. These then slowly travel along with a small piece of paper and stick to an antigen test line that only the coronavirus antibody will bond to. This makes the line visible and indicates that antibodies are present in the sample. These tests are more than 95% accurate and can give results within 15 minutes.

A major turning point in the battle against coronavirus will be the development of a successful vaccine. Vaccines often contain an inactive form of a virus that acts as an antigen to train your immune system and enable it to develop antibodies. That way, when it meets the real virus, your immune system is ready and able to resist infection.

But there are some limitations in that typical vaccine material can prematurely break down in the bloodstream and does not always reach the target location, reducing the efficiency of a vaccine. One solution is to enclose the vaccine material inside a nanoshell by a process called encapsulation.

These shells are made from fats called lipids and can be as thin as 5nm in diameter, which is 50,000 times thinner than an eggshell. The nanoshells protect the inner vaccine from breaking down and can also be decorated with molecules that target specific cells to make them more effective at delivering their cargo.

This can improve the immune response of elderly people to the vaccine. And critically, people typically need lower doses of these encapsulated vaccines to develop immunity, meaning you can more quickly produce enough to vaccinate an entire population.

Encapsulation can also improve viral treatments. A major contribution to the deaths of virus patients in intensive care is acute respiratory distress syndrome, which occurs when the immune system produces an excessive response. Encapsulated vaccines can target specific areas of the body to deliver immunosuppressive drugs directly to targeted organs and helping regulate our immune system response.

Its hard to exaggerate the importance of wearing face masks and washing your hands to reducing the spread of COVID-19. But typical face coverings can have trouble stopping the most penetrating particles of respiratory droplets, and many can only be used once.

New fabrics made from nanofibres 100nm thick and coated in titanium oxide can catch droplets smaller than 1,000nm and so they can be destroyed by ultraviolet (UV) radiation from sunlight. Masks, gloves, and other personal protective equipment (PPE) made from such fabrics can also be washed and reused, and are more breathable.

New fabrics made from coated nanofibres could produce better PPE. AnnaVel/Shutterstock

Another important nanomaterial is graphene, which is formed from a single honeycomb layer of carbon atoms and is 200 times stronger than steel but lighter than paper. Fabrics laced with graphene can capture viruses and block them from passing through. PPE containing graphene could be more puncture, flame, UV, and microbe-resistant while also being lightweight.

Graphene isnt reserved for fabrics either. Nanoparticles could be placed on surfaces in public places that might be particularly likely to facilitate the transmission of the virus.

These technologies are just some of the ways nanoscience is contributing to the battle against COVID-19. While there is no one answer to a global pandemic, these tiny technologies certainly have the potential to be an important part of the solution.

This article is republished from The Conversation by Josh Davies, PhD Candidate in Chemistry, Cardiff University under a Creative Commons license. Read the original article.

Read next: Schools are buying up surveillance technology to fight COVID-19

Read the original here:
How very tiny technologies are helping tackle the global pandemic - The Next Web

Read More...

AB8 Nano Sized Antibody – the Next Big Thing in Pandemic Prevention & Cure – Drew Reports News

Tuesday, September 15th, 2020

Highlights

This antibody component, which is 10 times smaller than a full-sized antibody, has been used to construct a drugknown as Ab8for potential use as a therapeutic and prophylactic against SARS-CoV-2.

The researchers report today in the journal Cellthat Ab8 is highly effective in preventing and treating SARS-CoV-2 infection in mice and hamsters.

Its tiny size not only increases its potential for diffusion in tissues to better neutralize the virus, but also makes it possible to administer the drug by alternative routes, including inhalation.

Importantly, it does not bind to human cellsa good sign that it wont have negative side-effects in people.

Ab8 was evaluated in conjunction with scientists from the University of North Carolina at Chapel Hill (UNC) and University of Texas Medical Branch (UTMB) at Galveston, as well as the University of British Columbia and University of Saskatchewan.

Ab8 not only has potential as therapy for the pandemic, but it also could be used to keep people from getting SARS-CoV-2 infections, said co-authorJohn Mellors, chief of the Division of Infectious Diseases at Pitt and UPMC. Antibodies of larger size have worked against other infectious diseases and have been well tolerated, giving us hope that it could be an effective treatment for patients with the disease and for protection of those who have never had the infection and are not immune. Xianglei Liu of Pitt is also co-lead author.

Wei Li, assistant director of Pitts Center for Therapeutic Antibodies and co-lead author of the research, sifted through antibody components and found multiple therapeutic antibody candidates in record time. (UPMC)

The tiny antibody component is the variable, heavy chain (VH) domain of an immunoglobulin, which is a type of antibody found in the blood. It was found by fishing in a pool of more than 100 billion potential candidates using the SARS-CoV-2 spike protein as bait.

Ab8 is created when the VH domain is fused to part of the immunoglobulin tail region, adding the immune functions of a full-size antibody without the bulk.

Like the Pitt and UPMC vaccine candidatePittCoVaccthat delivers an immunization through a spiky Band-Aid-like patch and overcomes the need for needles and refrigeration, the researchers are thinking outside the box when it comes to how Ab8 could be administered.

Its small size might allow it to be given as an inhaled drug or intradermally, rather than intravenously through an IV drip, like most monoclonal antibodies currently in development.

Abound Bio, a newly formed UPMC-backed company, has licensed Ab8 for worldwide development.

Dimiter Dimitrov, senior author of the Cell publication and director of PittsCenter for Antibody Therapeutics, was one of the first to discover neutralizing antibodies for the original SARS coronavirus in 2003. In the ensuing years, his team discovered potent antibodies against many other infectious diseases, including those caused by MERS-CoV, dengue, Hendra and Nipah viruses. The antibody against Hendra and Nipah viruses has been evaluated in humans and approved for clinical use on a compassionate basis in Australia.

Clinical trials are testing convalescent plasmawhich contains antibodies from people who already had the pandemicas a treatment for those battling the infection, but there isnt enough plasma for those who might need it, and it isnt proven to work.

Thats why Dimitrov and his team set out to isolate the gene for one or more antibodies that block the SARS-CoV-2 virus, which would allow for mass production.

The pandemic is a global challenge facing humanity, but biomedical science and human ingenuity are likely to overcome it, said Mellors, also Distinguished Professor of Medicine, who holds the Endowed Chair for Global Elimination of HIV and AIDS at Pitt. We hope that the antibodies we have discovered will contribute to that triumph.

This research was funded by National Institutes of Health grants, as well as UPMC; the Burroughs Wellcome Fund; a Canada Excellence Research Chair Award; Genome BC, Canada; Canadian Institutes for Health Research; and Canadian Foundation for Innovation.

To learn more about this research,watch a livestream on Sept. 15 at 2 p.m. ET.

Originally posted here:
AB8 Nano Sized Antibody - the Next Big Thing in Pandemic Prevention & Cure - Drew Reports News

Read More...

Nanomedicine – an overview | ScienceDirect Topics

Tuesday, August 25th, 2020

17.8 Commentary on Hurdles in Clinical Translation of Various Nanotechnology Products

Research regarding nanoconstructs development in the cancer treatment field has witnessed a noticeable increase after discovery of the EPR effect. However, the number of anticancer drugs that actually reached the market was considered extremely low, as out of 200,000 anticancer drugs only 15 made it by 2017 (Greish et al., 2018). The reasons why most of the nanomedicines cannot even reach the market are the hardship or inability to maintain detailed characterization of these products, unsuccessful manufacturing on large scales, and issues in their safety and efficacy. These hurdles require many developmental processes to overcome them including a precise understanding of every component and all the possible interactions between them, determination of key characteristics to understand in which possible ways they affect performance, and the extent of it. If key characteristics can be replicated under manufacturing conditions (scaling up), the efficacy of targeting at the site of action and their stability and sterility can be enhanced and/or assessed (Desai, 2012). The majority of these hurdles are summarized in Table 17.5 (Tinkle et al., 2014).

Table 17.5. Major Hurdles That Face the Commercialization of Nanomedicine

Lack of standard nano nomenclature: imprecise definition for nanomedicines

Currently used compounds/components for nanodrug synthesis often pose problems for large-scale good manufacturing (cGMP) production

Lack of precise control over nanoparticle manufacturing parameters and control assays

Lack of quality control: issues pertaining to separation of undesired nanostructures (byproducts, catalysts, starting materials) during manufacturing

Reproducibility issues: control of particle size distribution and mass

Scalability complexities: enhancing the production rate to increase yield

High fabrication costs

Lack of rational preclinical characterization strategies via multiple techniques

Biocompatibility, biodistribution and toxicity issues: lack of knowledge regarding the interaction between nanoparticles and biosurfaces/tissues

Consumer confidence: the publics general reluctance to embrace innovative medical technologies without clearer safety or regulatory guidelines

The relative scarcity of venture funds

Ethical issues and societal issues are hyped up by the media

Big Pharmas continued reluctance to seriously invest in nanomedicine

Patent review delays, patent thickets, and issuance of invalid patents by the US Patent and Trademark Office

Regulatory uncertainty and confusion due to baby steps undertaken by US Food and Drug Administration: a lack of clear regulatory/safety guidelines

One of the major concerns related to NPs is their potential incompatibility and toxicity. Studies showed that inhaling NPs can cause pulmonary inflammation as well as inducing endothelial dysfunction that might lead to further complications in the cardiovascular system. A study for evaluation of iron oxide toxicity showed that monocyte-mediated dissolution and phagocytosis of the NPs have caused severe endothelial toxicity by initiating oxidative stress. Nanomaterials used in oral DDS have been shown to accumulate in hepatic cells, which might induce the immune response and eventually cause permanent damage to the liver. The accumulation of NPs in cells has been found to cause cancer by transforming cells into the tumorous state (Jain et al., 2018; Riehemann et al., 2009). Thus, handling these nanosystems requires special equipment and caution, which increases the cost of the production process and requires further investigations of the safety of nanomaterials to have a better understanding and optimize safety during manufacturing (Hammed et al., 2016). Production of NPs in the laboratory often requires complex, multistep synthesis processes to yield the nanomaterials with the required properties. Aside from the complexity of the process, controlling conditions such as temperature and concentrations precisely is significant to achieve homogeneity of NPs in terms of desired characteristics. However, retaining temperature and concentration in large systems is harder to achieve resulting in NPs with different characteristics (Gomez et al., 2014).

NPs tend to aggregate forming clusters with several microns in size. Aggregation of NPs alters their characteristics such as reactivity, transport, toxicity, and risk in the environment. Dissolution reduces when aggregation occurs due to the decrease in available surface area that will eventually reduce the activity of NPs. For example, dechlorination rate of CT (carbon tetrachloride) by magnetite NPs has shown to decrease when aggregation of the NPs increases resulting in an inverse relationship between dechlorination rate of carbon tetrachloride and aggregation of magnetite NPs (Hotze et al., 2010; Hou and Jafvert, 2009).

All these requirements are extremely important because the majority of the nanomedicines have failed to reach the commercialization step even though their efficacy in animal models was considerably high. Due consideration must be given regarding the several difficulties such as their low targeting, low safety, low efficacy, heterogeneity of disease between individuals, inability to scale-up successfully, and unavailability in determining a convenient characterization methods (Agrahari and Agrahari, 2018; Hare et al., 2017; Kaur et al., 2014). These hurdles that face the research process of accelerated translation are summarized in Fig. 17.8 (Satalkar et al., 2016).

Figure 17.8. Major issues that face accelerated translation process of nanoparticles.

Therefore, more understanding in all aspects of nanomedicine production, characterization, and clinical processes must be fulfilled to control and improve the development processes, and increase the efficacy of the translational methods. Other significant hurdles hindering clinical translation are the insignificant incentives regarding technology transfer, as well as socioeconomic uncertainties along with the safety problems faced. In the majority of cases, consideration of commercialization aspects in early stages of development is hardly even considered thus eliminating the market-oriented development (Rsslein et al., 2017).

Nanomedicines face tough, challenging concerns when it comes to determining the applicable analytical tests in terms of chemical, physical, or biological characterization. This is mainly achieved due to their complex nature in comparison with other pharmaceutical products. Hence, there is a need for more complex and advanced levels of testing to ensure a full accurate characterization of nanomedicine products. Quantification of each component of nanomedicine is considered essential alongside the identification and evaluation of interactions between them. For more possibility in achieving successful manufacturing processes with reproducibility, these products should be investigated and understood more during the early developmental stages to identify their key characteristics. The challenges for nanomedicine during scale-up and manufacturing are considered relatively unique because other pharmaceutical manufacturing processes systems are not three-dimensional multicomponent in nature on the nanometer scale. Therefore, a certain series of obstacles in the scale-up process is required. To reach the desired safety, pharmacokinetic and pharmacodynamic parameters to produce the therapeutic effect are needed. These are further determined by the proper selections of the essential components, determination of the critical manufacturing steps, and key characteristics identification. Several methods of orthogonal analysis are essential for in-process quality controls of nanoparticle products and any deviations from key parameters could result in a significant negative impact on both the safety and efficacy of nanomedicines (Desai, 2012).

Each step in the manufacturing process of NPs must be understood extensively with the need of experienced technicians. The development process also requires more enhancements in both complexity and cost. Inadequate data regarding scaling-up processes of nanomedicine products is a major concern in the commercialization step as there are only a few reports supporting scaling-up developments. Many formulation methods have been developed for manufacturing nanomedicine products. The most common methods are nanoprecipitation and emulsion-based approaches. Generally, formulations are prepared either by precipitating the dissolved molecules (bottom-up method) or by reducing the size of larger drug particles (top-down method). Removal of the solvent in the bottom-up method is not an easy process and it cannot be controlled well either, thus explaining why this method is less often applied in industrial manufacturing (Agrahari and Agrahari, 2018; Vauthier and Bouchemal, 2009). Investments in innovative projects face several issues with the major one being the knowledge that should be obtained from the innovation. Its confidentiality is easily breached when a company uses that knowledge as it cannot prevent other companies from using it. Thus, investors are not attracted to this type of project because the total return on the investment cannot be easily appropriated (Morigi et al., 2012).

The complexities in formulating nanoproducts on large scales are due to the inability of optimization of formulation processes and achieving reproducibility. Whereas formulation steps including size reduction, homogenization, centrifugation, sonication, solvent evaporation, lyophilization, extrusion, and sterilization can be easily optimized on small-scales, its still a challenging process on large-scales. Accordingly, variations between batches cannot be controlled sufficiently thereby limiting the possibility of nanomedicine to get through commercial translation (Anselmo et al., 2017; Desai, 2012).

Another problem is that even slight changes in either the formulation or the manufacturing process can have a significant effect on the nanomedicine physiochemical properties (crystallinity, size, surface charge, release profile), which will ultimately influence the therapeutic outcome. Most of the pharmaceutical industrial facilities cannot manufacture nanomedicines because of the lack of the right equipment for the process. As nanomedicine manufacturing usually involves the use of organic solvents, the ability to correctly process and handle nanoproducts is crucial to control their safety and sterility (Anselmo et al., 2017; Desai, 2012; Kaur et al., 2014). These steps require an expensive and complicated equipment, well-trained staff, and precise control to get the required product in the right quality (Desai, 2012; Kaur et al., 2014; Ragelle et al., 2017).

To date, only 58 nanoformulations are approved based on their clinical efficacy but only a quarter of them are meant for cancer treatment. Majority of the nanoformulations could not even be reproduced successfully due to several factors including the study design, overall analysis, protocols, data collection, and the quality and purity of materials used. Besides, the poor establishment of the correlation and prediction of safety and efficacy of the nanomedicine on patients hinders the successful DDS. Targeting and drug accumulation of anticancer drugs in the site of action is considered relatively poor in mouse models. Many nanoformulations were faced with failure in different clinical trial phases. Some of them got approved but then withdrawn from the market such as peginesatide. Unfortunately, the increased failures will most probably affect the development movement in the pharmaceutical industry (Greish et al., 2018).

At the present time, regulatory agencies such as the FDA and EMEA are examining every new nanomedicine on a product-by-product basis. They are considered a unique category due to the fact that there are no true standards in their examination process (Desai, 2012). Two of the major regulatory issues that emerged at the start of nanomedicine is the lack of scientific experts in the FDA and the difficulty in classifying the product (Morigi et al., 2012). The unique characteristics of nanomedicines are directly related to their regulation hurdles, which is the same as other pharmaceutical systems such as liposomes and polymeric systems (Sainz et al., 2015).

Researchers keep investigating nanomedicines when attached to prodrugs, drugs, tracking entities, and targeting molecules. Development of robust methods and assays in quality control of nanomedicines are required for more effective monitoring and characterizations. Also, estimation of their overall performance in releasing drugs, binding to proteins, and the specificity in cellular uptake must be considered (Sainz et al., 2015; Tinkle et al., 2014).

Nanomedicine products are both complex and diverse requiring explanation of challenges to have a clear definition and an effective regulation. The lack of regulatory guidelines for these products hinders their clinical potential. Drug regulatory authorities must keep up with the rapid pace of the knowledge and technological development as they play a major role translating nanomedicines towards the market. The European Medicines Agency (EMEA) and the FDA have different requirements in evaluating new nanomedicines as well as different definitions regarding nanomedicine. Agreeing on specific regulatory procedures internationally is very important to ease the translational researches of nanomedicines. Also, better long-term monitoring of toxicity should be achieved by prolonging postmarketing surveillance especially for a patient with chronic diseases (Sainz et al., 2015; Tinkle et al., 2014).

Nanomedicines just like any other pharmaceutical formulations must offer higher value to patients to become commercially successful, and have better efficacy and safety. New nanomedicine products follow the same steps in clinical trials as other drugs. It starts with preclinical tests, then be submitted to get the IND (investigational new drug) approval and following that it enters the three stages of clinical trials, one after another to evaluate safety and efficacy of the new drug (Agrahari and Agrahari, 2018).

In recent years, toxicities caused by nanomedicines have drawn attention and been recognized to be unique to nanoparticulate systems. Hence, a minimum set of measurements for the nanoparticle like surface charge, size, and solubility are monitored so as to predict the possible toxicity of NPs. Besides, NPs can stimulate the immune system by acting as an antigen. Immunogenicity is mainly affected by the size of the nanoparticle, its surface characteristics, hydrophobicity, charge, and solubility. Hematologic safety concerns have also been observed such as hemolysis and thrombogenicity (Desai, 2012).

In vivo and in vitro studies provide the proper characterization of the interactions between the product and the biological system. The problem is that the data attained from current toxicity tests are not from clinical trials and it cannot always be extrapolated to humans. Monolayers of cell cultures are currently used to characterize immunogenicity, drug release, cellular uptake, and toxicity. However, the cellular uptake process of nanoformulations is majorly influenced by physicochemical characteristics. Thus, 3D cell systems will probably provide better outcomes (Gupta et al., 2016). More caution should be given when handling any nanosized powder due to the ability of such particles to penetrate the skin and because it can also show pulmonary toxicity (Agrahari and Hiremath, 2017; Nel et al., 2006).

Here is the original post:
Nanomedicine - an overview | ScienceDirect Topics

Read More...

Nanotechnology In Medical Applications Market To Eyewitness Massive Growth Trends Market Research 2017 to 2022 – Scientect

Tuesday, August 25th, 2020

Theglobal nanomedical marketwas valued at $134.4 billion in 2016. This market is projected to grow at a compound annual growth rate (CAGR) of 14.0% from 2017-2022, and should reach $293.1 billion by 2022 from $151.9 billion in 2017.

Request For Report[emailprotected]https://www.trendsmarketresearch.com/report/sample/12261

Report Scope:

This report discusses the implications of technology and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting nanomedicine are reviewed, and the nature and structure of the nanomedicine industry are discussed with profiles of the leading 60+ companies, including recent merger and acquisition (M&A) activity. Five-year sales forecasts are provided for the national markets including the major therapeutic categories of products involved. Specific product categories quantified include diagnostics, cancer, CNS, anti-infective agents, cardiovasculars and anti-inflammatories.

Report Includes:

An overview of the global markets for nanotechnology used in medical applications Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022 A review of technologies involved, in-depth analysis of applications in practice, and evaluation of future or potential applications Information on many significant products in which the nano dimension has made a significant contribution to product effectiveness A look at the regulatory environment, healthcare policies, demographics, and other factors that directly affect nanotechnology used in medicine Analysis of the markets dynamics, specifically growth drivers, inhibitors, and opportunities Coverage of strategies employed by companies specializing in nanomedicine to meet the challenges of this highly competitive market

Get Complete TOC with Tables and [emailprotected]https://www.trendsmarketresearch.com/report/discount/12261

Summary

Nano-enabled medical products began appearing on the market over a decade ago, and some have become best-sellers in their therapeutic categories. The principal areas in which nanomedical products have made an impact are cancer, CNS diseases, cardiovascular disease and infection control. The Summary Table gives estimates of the historical and current markets for these nanomedicine areas with a forecast through 2022.

The U.S. market is by far the largest in the global nanomedicine market and is set to continue to dominate the world marketplace; however, other national markets are expected to increase their shares over the next five years.

Reasons for Doing the Study

Nanomedicine is already an established market. Unlike some other potential applications of nanotechnology, which are still largely experimental, nanomedicine has already produced some significant products in which the nano dimension has made a significant contribution to product effectiveness. Now that aspects of the nanomedicine market are established, it is appropriate to review the technology, see its practical applications so far, evaluate the participating companies and look to its future.

<<< Get COVID-19 Report Analysis >>>https://www.trendsmarketresearch.com/report/covid-19-analysis/12261

See more here:
Nanotechnology In Medical Applications Market To Eyewitness Massive Growth Trends Market Research 2017 to 2022 - Scientect

Read More...

Interview: The NDB team on its revolutionary nano-diamond batteries – New Atlas

Tuesday, August 25th, 2020

A cheap, safe, self-charging battery that delivers high power for decades without ever needing a charge? That's a game changer. California-based company NDB is making some outrageous promises with its nano-diamond battery technology, which could completely disrupt the energy generation, distribution and provision models if deployed at scale.

Each of these batteries, which can be built to fit any existing standard or shape, uses a small amount of recycled nuclear waste, reformed into a radioactive diamond structure and coated in non-radioactive lab diamonds for safety.

We explained the technology in detail in our original NDB nano-diamond battery breakdown, but we also had the opportunity to speak with members of the NDB executive team. CEO Dr. Nima Golsharifi, COO Dr. Mohammed Irfan and Chief Strategy Officer Neel Naicker joined us on a Zoom call to talk about the technology and its potential for disruptive change.

What follows is an edited transcript.

Dr Nima Golsharifi: Our battery is based on the beta decay and alpha decay of radioisotopes. The technology we have encapsulates this radioisotope in a very safe manner, which allows it to be used in basically any application that current batteries are being used for.

Loz: The particular type of carbon that you're using, where do you get that?

Nima: Basically we're using a range of different isotopes, not just one particular one, but access to these are through different methods. We have some partners in collaboration at the moment that can provide us with them.

But they're basically taken from nuclear waste. So we can recycle them and use the raw materials for our application. But we can also synthesize it in large scale in our facility. So both are possibilities.

Loz: OK. So what part of a nuclear reactor creates this waste? What's it doing before it becomes waste?

Nima: Basically, some parts of the nuclear reactor, like the moderator and the refractor, are being exposed to radiation from the fuel rods. Over time they become radioactive themselves. That's the part that they have to store as nuclear waste.

So this part could be taken away, and through some process, either gasification or some other processes we've designed, we can convert that into a useful raw material for our batteries.

Sheikh Mohammed Irfan: Dr. Nima, maybe you can also talk about how big of a waste problem that is for the nuclear industry currently.

Nima: Sure. At the moment, their expenditure is more than a hundred million dollars every year. Nuclear waste is a very large issue across the world. And beside this, there's basically no other way to re-use it in a safe solution.

So what we're doing covers two challenges in one. Converting nuclear waste into a battery that generates power in a very safe manner. Once this battery is used and it can have a very long life span it becomes a very safe byproduct that's of no harm to the environment.

Loz: Right. So I saw a number somewhere that these batteries can last for 28,000 years.

Nima: Let me correct that. It depends on the type of radioisotope you're using, and for every application the lifetime is different. But what we can say is that the battery would operate for the lifetime of the application itself, for sure. For some applications, much higher. So if you're talking about electric vehicles, our battery could run for around 90 years without the requirement of recharging.

When it comes to something like consumer electronics, it'd be more like 9 years. In some small sensor applications, it can go for up to 28,000 years.

NDB

Loz: I understand. So what sort of quantities of this waste are there around the world? Is this super common stuff, or is it reasonably finite?

Nima: Basically we're covering two different kinds of nuclear waste. One is intermediate, and the other is high level. So there will be a time where we have recycled the entire amount of nuclear waste, and we'll need new solutions for the raw material. But as I mentioned, we'll be able to produce this raw material through other methods, including transmutation.

That's a process that's currently being used, and not something we've invented ourselves. It was invented by MIT, and it involves a centrifuge to separate out the isotopes. The main ingredient is nitrogen, which is the major component of air, so it's a very cheap solution.

Loz: So you've got your nuclear waste, it's obviously dangerous for humans. How does it become safe to be used in a battery?

Nima: Basically, we can generate a high amount of cover from the radioactive substance. We're using a combination of technologies within our structure that can make it very safe to users. Mainly it comes down to the fact that we're using diamond structures.

Diamond itself has different interesting properties. It's one of the best heat sinks available at the moment, for example. That on its own covers thermal safety. When it comes to mechanical safety, diamond is one of the strongest materials in the world. 11.5 times stronger than steel. So again, that itself makes the battery tamper-proof and safe.

In addition to that, we have a combination of other technologies, including the implantation of the radioisotopes within the diamond structure, which stops the spread of the radioisotopes even if the structure is broken down which is kind of impossible without access to specific tools like lasers and others.

So in general I can say it's a combination of technologies that we've either innovated or invented that create a very safe structure as a battery.

Irfan: I'd like to add to that, that using radioisotopes as a source for energy is not new. We have nuclear medicine, where patients are treated with controlled equipment, which has always given effective results. Similarly, we have had nuclear-powered submarines and aircraft carriers. Of course, that's a completely different process, but it's been able to successfully and safely deliver power and energy without safety issues.

What Dr. Nima has highlighted is that the choice of diamond as a material is one of the strongest natural materials, and it acts as a powerful shielding and protection mechanism.

Loz: Right. Can you describe how the energy is extracted and harnessed?

Nima: Maybe I can give an example that could help you understand. Let's go to solar cells, everyone's familiar with those. These convert the energy from light radiation into electricity in photovoltaic cells.

In our case, we're converting the radiation from alpha/beta decay alpha and beta radiation directly into electricity. And the mechanism we're using is simple crystalline diamond. As I mentioned before, we have another layer, which is fully crystalline diamond, creating extra shielding and safety for this structure.

Neel Naicker: What Nima's describing is how the radioactivity produced by the body is actually more than what you get from these batteries. They're quite safe.

Loz: So in terms of evaluating batteries for use in cars, eVTOLs and things like that, the main metrics seem to be energy density, power density, safety in a crash, that sort of thing. Do you know what sort of figures you're looking at with these batteries?

Nima: When it comes to energy density, the energy density of a basic radioisotope is far beyond anything else on the market.

When it comes to power density, the solution we have will give a higher level. But compared to the way that energy density is higher, power density is not that much higher. But it's still significantly better than other batteries in the market.

And as far as crashes, no crash could break down our structure at all. Because you're using the diamond, and the specific mechanisms that make it stronger. The only way to get through the structure we have is the use of specific tools and lasers, which are quite expensive.

Neel: Another way to look at this is to think of it in an iPhone. With the same size battery, it would charge your battery from zero to full, five times an hour. Imagine that. Imagine a world where you wouldn't have to charge your battery at all for the day. Now imagine for the week, for the month How about for decades? That's what we're able to do with this technology.

Loz: It would strike at the heart of the disposable model the phone companies tend to use.

Neel: You've hit the nail on the head there. A couple of things. One is the ability for us to power things at scale. We can start at the nanoscale and go up to power satellites, locomotives Imagine that.

Secondly, we're taking something that's a big negative radioactive waste, very dangerous and turning it into something productive that provides electricity.

The third thing is that we wanna use this technology to get low-cost electricity to places that need it. We've now disrupted the whole mechanism of the creation and storage of power. There's a lot of infrastructure needed before you can flip a light switch and a light comes on.

But with what we've created, you don't need that infrastructure. You could put one of these batteries in a home, and boom, you've eliminated the whole infrastructure. Imagine the disruption that's gonna cause, for good or for bad. It'll upset a few people.

We've taken something that's really harmful to the environment, a problem, and created energy. And for places that don't have the electrical infrastructure in place, we want to provide that at a very low cost.

NDB

Loz: Let's talk about cost a little. Obviously lithium batteries cost a lot, they're a primary component of the cost of electric vehicles. Do you guys have a sense for what these things could cost in a commercial environment?

Nima: Yes, we've done financial modelling around this. A lot of applications have been considered. What we can say is it'll depend on the application, but it should be at a good competition level with current lithium-ion batteries.

In some cases, you're a little bit higher in price for production, and in others, when it goes to scale, we're a cheaper solution. Let me give you an example. Take the battery for a Tesla car, it costs somewhere in the region of US$9-10K. Our battery will cost something in the region of US$7-8K. But it's different in different applications.

Loz: So, cheaper and it never needs charging, and it lasts for vastly longer than any lithium cell.

Irfan: Not only is it a few thousand cheaper for the battery pack, but ours recharges itself. So on a Tesla, you need to recharge, stop, over time the battery wears itself out. Ours lasts for a long time.

We'll probably have them available under some sort of subscription model, pay as you go, but it'll be substantially cheaper than what the mechanism is today for a Tesla car.

Loz: Extraordinary. How far along is this technology? How far are we off mass production? Where are you at with prototyping and testing?

Nima: We're in the prototyping stage at the moment. We've completed the proof of concept, and we're about to start the commercial prototype. However, the pandemic has happened, and the lab has been shut down for some time.

But basically once the laboratories are open, we do require around 6-9 months to complete our commercial prototype, and following that to go through the regulatory process, to bring the first few applications for the battery into the market in less than two years' time.

Loz: So it's not far off.

Neel: Just to give you an example, we'll take Google, which has data centers all across the world. Amazon, Facebook, all of these companies. In confidential conversations we've had with some of these parties, we've spoken about how they use and dispose of more Uninterruptible Power Supplies (UPS) than anyone on the planet. Google always has to be on. And those UPS units have a use by date, they have to discard them.

Our product will be able to support that, while reducing the carbon footprint, and lasting far, far longer. That's a game changer when you consider how big an operation something like AWS is. It'll be a huge product for that.

A secondary product will be for the satellite market, where there'll be no regard for whether it's radioactive or not. Low-power satellites, we'll be able to power those for a long, long time without having any regard to whether they're facing the Sun, or getting any Sun on their solar panels, or whatever.

It changes the whole dynamic. Not only have we disrupted the whole energy infrastructure for creating and delivering power, we can also make big changes to the business model for a lot of companies. Big concerns can just become negligible.

This will change a lot of industries. In the future, we could look at using these to power nanorobots moving inside the body. It works from the nanoscale up to large scale. We think it'll be very impressive.

Loz: So the limits on this technology will be what, availability of the raw materials? Regulations? Do you see any regulatory barriers?

Irfan: It's a good question. We've done a comprehensive study on the regulatory and compliance aspects of our technology. Fortunately there are other devices already on the market that use radioisotopes and radioactive material inside them. Some are in the medical industry, like pacemakers. There are already different types of regulations in place.

So the matter here would be our design complying to those regulations, and we've been doing that over time.

Neel: In your home, you'll have smoke detectors, right? All of those have the same radioactivity as well. That's one point.

When it comes to availability, there's enough raw materials out there that we can develop for a long time. That's not the issue. Also, on the regulatory side there are some markets we can go into immediately without any concerns there. Aerospace, military, many others where there aren't the same requirements for compliance.

For a car, it may be different. For a hearing aid, it may be different, or a consumer product. But there are some applications where it won't be a problem at all.

Loz: Right. This is perhaps a bit of a crass question to ask, but do you guys have to pay for this nuclear waste, or are people paying you to take it away?

Irfan: (Laughs) I'm glad you brought that up! We've got a few places that have offered to pay us to take it away. It's a nuisance for them. They have to store it, and you can imagine the regulations around that. In many cases, they have to keep the public a certain distance away. They'll actually pay us to take this stuff away.

So it's a secondary opportunity for us from a revenue standpoint, and we've discussed this with several partners.

Loz: What a wonderful business to be in, where you're paid to take your own raw materials.

Neel. I wanna drive one thing home. If you take a look at the map of energy use in the world, and the map of wealth in the world, they're very similar. One thing we're trying to do with our application is trying to get some of these devices out to places where kids don't have electricity to do their homework, or to power clean water technology.

We're very adamant that this be a component of our business. And while we can't mention too many names, we've spoken with several big partners who would support this effort. Some of these companies feel they need to do good in the world, and providing electricity to places across the world that don't have it is a great opportunity for them.

Again, they don't have the huge infrastructure in place. But we don't need the infrastructure. We don't need power stations, or power lines, or any of that, to provide power. We're adamant as a team that we will give back in a major way that today's infrastructure won't allow.

Loz: In terms of the IP around this, how much do you guys own, and how much competition do you expect?

Irfan: Right now, we have patents pending around our technology. I think we're quite ahead of the competition that exists in the market, we started much earlier than the others and our technology is more advanced.

We thank the NDB team members for their time and look forward to learning more as development progresses.

Source: NDB

Read the rest here:
Interview: The NDB team on its revolutionary nano-diamond batteries - New Atlas

Read More...

Nanorobots Market Incredible Possibilities, Growth with Industry Study, Detailed Analysis and Forecast To 2026 – Scientect

Tuesday, August 25th, 2020

The latest research on the Global Nanorobots Market that covers growth factor, future trends, and focuses on overall knowledge that can help to make decisions on the current market situation. Nanorobots report provides information on Size, Type, Service, Output, Revenue, Growth Rate, Gross Margin, and opportunities with potential risk analysis. The Nanorobots research study defines top company profiles with trends around the world present in the market. The report also discusses financial developments with the effect of COVID-19 on the market of Nanorobots across years. TheNanorobots research executes financial adjustments that occur on the market year after year, with details on future opportunities and risks to keep you ahead of the competitors.Nanorobots market research has driven you to expand your company.

Major Players Covered in this Report are:

Bruker, Jeol, Thermo Fisher, Ginkgo Bioworks, Oxford Instruments, Ev Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract, Nanonics Imaging, Novascan Technologies, Angstrom Advanced, Hummingbird Scientific, Nt-Mdt Spectrum Instruments, Witec

To Request an Exclusive Sample Report for Nanorobots Market @ https://www.marketgrowthinsight.com/sample/132933

Scope of the Nanorobots Market Report:

The demand for Nanorobots is projected to expand, during the forecast period, from USD million in 2020 to USD million by 2025. The global market report is a systematic study that focuses on the overall demand structure, development trends, business models and business of top countries in the global market for Nanorobots. The study focuses on well-known global Nanorobots suppliers, market segments, competition and the macro market.

The Nanorobots study focuses on the prospects for growth, constraints, and market analysis. The research offers Porters five-force Nanorobots industry analysis to understand the effect of various factors such as supplier power bargaining, competitor competition, new entrant challenge, competitor risk, and buyer bargaining power on the market.

Market Segmentation:

A brief overview of the global Nanorobots market has been presented according to the most recent report. TheNanorobots evaluation notes the concept of service/product in many end-user sectors along with other implementations of these goods or services. The Global Nanorobots Market Report presented a thorough assessment of the latest industry developments, extensive regional analysis, and competitive analysis for the 2020-2025 review period.

Geographically, the detailed analysis of consumption, revenue, Nanorobots market share and growth rate, historic and forecast (2015-2025) of the following regions are covered:

North America (United States, Canada, Mexico)Europe (Germany, UK, France, Italy, Spain, Russia, Others)Asia-Pacific (China, Australia,South Korea,Japan, India, Southeast Asia, Others)Middle East and Africa (UAE, Saudi Arabia, Egypt, South Africa, Nigeria, Others)South America (Brazil, Argentina, Columbia, Chile, Others)

Ask for Discount on this Premium Report @ https://www.marketgrowthinsight.com/discount/132933

In this study, the years considered to estimate the market size of Nanorobots are as follows:

KEY QUESTIONS ANSWERED:

For More Details On this Report: https://www.marketgrowthinsight.com/inquiry/132933

About Us-

Market Growth Insight 100% Subsidiary of Exltech Solutions India, is a one stop solution for market research reports in various business categories. We are serving 100+ clients with 30000+ diverse industry reports and our reports are developed to simplify strategic decision making, on the basis of comprehensive and in-depth significant information, established through wide-ranging analysis and latest industry trends.

Contact Us:

Direct Line: +1 3477675477 (US)Email: [emailprotected]Web:https://www.marketgrowthinsight.com

Read the original post:
Nanorobots Market Incredible Possibilities, Growth with Industry Study, Detailed Analysis and Forecast To 2026 - Scientect

Read More...

Book Review: What Can India’s Embrace of Nanotech Tell Us About India’s Science? – The Wire Science

Friday, August 21st, 2020

A glass nanoparticle suspended in an optical cavity. Photo: uclmaps/Flickr, CC BY 2.0.

Nanotechnology may not be a familiar term to many although nanotechnology-based products are available in the market and many consumers use them. Thanks to Nano Mission, an initiative funded by the Government of India through the Department of Science and Technology from May 2007, India has made great strides in nanosciences and engineering.

In this regard, Nanoscale, a new book by Pankaj Sekhsaria, a policy researcher at the Centre for Technology Alternatives for Rural Areas, IIT Bombay, doesnt eulogise the technology and its achievements nor does it criticise them and their deployment and risks.

Instead, Sekhsaria takes an atypical tack to set out what is possible, offering us new ways to conceive of and evaluate research. Through four case studies, he attempts to understand the links between science, technology and society at different sites and at different scales as if to ensure we are aware of what all is possible before we embark on our respective critical journeys. They are:

1. Developing a cutting-edge microscope at a university in Pune, despite severe constraints

2. Using nanotechnology to validate some components of a traditional Ayurvedic preparation

3. The failure of an innovative product a nano-silver-coated ceramic candle used to purify water in households

4. Nanotechnology-based treatment protocols for retinoblastoma, a cancer that affects children

The first case study concerns the construction of a scanning tunnelling microscope by C.V. Dharmadhikari at the University of Pune, using a variety of materials, including nanoparticles. Sekhsaria describes how Dharmadhikari built this sophisticated device from scratch, indigenously, and which he and his team now use for their research.

With this in mind, Sekhsaria invokes the concept of jugaad and the culture of innovation in laboratories around India. However, Eric von Hippels user innovation theory offers a better explanation: that more innovation is driven by intermediate or end users, at the site of consumption, which is then integrated by suppliers. In this case, Dharmadhikari is both a user and an innovator: he first developed the instrument and then, in the course of using it, continued to make minor modifications to better suit his and his peers purposes.

In fact, this would be true of most scientific instruments which are constantly attended to by a community of user-innovators of PhD students, postdoctoral researchers and investigators. As a result, in an ecosystem where resources are scarce and grants and funds are constantly shadowed by uncertainty, such DIY endeavours contribute more innovation and help adapt sophisticated technologies for more local conditions including nanotechnology.

Sekhsaria subsequently describes the fate of Dharmadhikari et als scanning tunnelling microscope, and compares it to that of similar innovations elsewhere in India. However, he stops short of discussing the range, utility and novelty of such instruments and how they have enabled Indian scientists to pursue science despite their constraints. Nor is there mention of how common such solutions are common across disciplines and institutions. Of course, user innovation can occur even when new instruments are acquired but if building instruments from scratch is very widely practised, it deserves a fuller study, as an important dimension of doing science in India.

The second case study concerns the use of nanotechnological tools to validate the components of a traditional Ayurvedic preparation, called bhasmas, and related work at the Centre for Nanobioscience, Agharkar Research Institute, Pune. Using the studies of Rinku D. Umrani, Sekhsaria highlights how the dialog between modern science (nanotechnology) and traditional medicine (Ayurveda) is necessary, although there are skeptics on both sides.

While the usefulness of traditional medicine is well known and accepted, it is often debunked as unscientific or considered to be scientifically unprovable. But a dialog could help better understand each system from the other systems perspective, paving the way for potentially fruitful collaborations.

With the specific example of bhasmas, Sekhsaria focuses the discussion onto the challenge of checking if Ayurveda can provide an alternative way to manage diabetes. Umranis work suggests that the mechanisms of action of some Ayurvedic preparations, including bhasmas, involve reactions involving nanoparticles. But instead of limiting himself to a yes/no answer, Sekhsaria argues that validation is necessary but a dialog as equals is more important to facilitate further research that, by extension, the introduction of radical new technologies brings with it radical new opportunities to improve the way we organise and conduct research.

Also read: Why Elon Musk Isnt Right About Nanotechnology Being BS

The third case study highlights how an innovation perceived to be locally useful to provide good quality drinking water at the household level using nanosilver-coated candles failed in the market. Researchers at the International Advanced Research Centre for Powder Metallurgy and New Materials (ARCI), Hyderabad, had developed these devices, essentially ceramic candles coated with nanoparticles of silver that could filter out some bacterial species from water.

But for the fact that they were simple to use, required less maintenance and were locally produced, they flopped at the market because they rested on the products uniqueness instead of adjusting for consumer behaviour and aspirations. The ceramic candle platform itself was becoming obsolete as a water purification technology, and newer entrants, ranging from advanced filters to ultraviolet and reverse-osmosis systems, all of which trapped more than bacteria, heightened buyers expectations.

Nonetheless, the candles were still useful, especially in low-cost settings. So Sekhsaria contends that such products shouldnt have been left at the mercy of market forces and that the government should have stepped in with subsidies. In fact, he challenges the idea that nanosilver-coated candles are obsolete per se, and argues that obsolescence is linked to infinite demands and consumption and that ARCI might have had more success if it had involved end-users during the product development process. According to him, there is also scope to recalibrate, renegotiate and revive the product, especially if were willing to learn from our mistakes.

The fourth case study is on treating retinoblastoma in female children. While nanotechnology is expected to offer better solutions like using gold-based nanoparticles to destroy cancer cells in a photothermal process the grim reality is that in some cases, parents prefer not to treat the child and let her die. This is because when children afflicted with retinoblastoma are not treated on time, they may lose eyesight and sometimes even their lives. In this regard, Sekhsaria spotlights how clinicians often talk to these childrens parents as if they are activists, and attempt to educate parents.

There is hardly any categorised data on retinoblastoma in India and how different sections of society have responded to it. It is true that technology is no panacea and the social complexities have to be taken into account but the complexity cant be reduced to that of only discrimination.

Sekhsaria discusses how girls and women are discriminated against, and how some parents choose to ignore new technologies that offer better treatment in favour of letting them die. However, his foundation is almost entirely anecdotal, based on discussions he had in two institutions in Hyderabad and Chennai. His analysis would have been enriched by including examples from more institutions, even if only in these cities, and could have fortified Sekhsarias arguments.

As such, the reader is unable to generalise from his examples as to the fraction of parents in the country who decide thus and why, nor whether the parents of male children behave the same way. Moreover, Sekhsaria discusses only those cases where parents didnt treat the child even if they had the option to do so, or accessed treatment when the retinoblastoma had entered the later stages.

Instead, the discussion could have covered the class and access to treatment dimensions. Unless we know how different sections of society respond to all the options available to them, the books view remains one-dimensional and unable to help us understand the technology-society interface. Nanotechnological solutions are not yet in vogue and are years away from widespread adoption. And even if nanotechnology has to have a positive impact, its success depends on the solutions affordability, accessibility and the decisions of parents who need to decide what is best for their children and themselves.

In fact, overall, Nanoscale often doesnt go far enough to flesh out the stories it uses to make its point about the unique prevalence of nanotechnologies across four very different slices of society, as if the book is attempting to anticipate the nanos outsized impact on society, and even social relations, in future.

Currently, India publishes the third-highest number of research papers on nanotechnology in the world. Nanotechnologies themselves have applications in sectors ranging from agriculture to textiles, from medicine to construction materials. For example, nano-fertilisers can help increase the efficiency with which plants use nutrients in the soil and help reduce nutrient run-off. Researchers have also used precepts of nanotechnology to improve hydrogen-based renewable energy technologies.

Also read: Why India Needs Nanotechnology Regulation Before it is Too Late

In this regard, Nanoscale provides a new perspective on nanotechnology in India and asks important questions about the corresponding science, technology and policies of innovation. Sekhsaria also successfully subverts conventional wisdom on innovation and attempts to link jugaad with sophistication, calls for dialog between modern science and traditional medicine, and highlights how the market can destroy innovations even as it patronises more expensive technology.

As such, Sekhsarias reluctance to pronounce verdicts works to the books advantage because, by highlighting the gap between traditional ideas of innovation in laboratories and the ground reality, he is able to contend that we can utilise nanotechnologies to a fuller extent by applying them to areas where there is a contest of paradigms or worldviews.

Krishna Ravi Srinivas works at Research and Information Systems for Developing Countries, a policy research think-tank. The views expressed here are the authors own.

See the article here:
Book Review: What Can India's Embrace of Nanotech Tell Us About India's Science? - The Wire Science

Read More...

Healthcare Nanotechnology (Nanomedicine) Market Analysis, Key Players, Industry Segments And Forecast To 2026 – The News Brok

Friday, August 21st, 2020

The Healthcare Nanotechnology (Nanomedicine) market report 2020-2026 provides in-depth study of market competitive situation, product scope, market overview, opportunities, driving force and market risks. Profile the Top Key Players of Healthcare Nanotechnology (Nanomedicine), with sales, revenue and global market share of Healthcare Nanotechnology (Nanomedicine) are analyzed emphatically by landscape contrast and speak to info. Upstream raw materials and instrumentation and downstream demand analysis is additionally administrated. The Healthcare Nanotechnology (Nanomedicine) market business development trends and selling channels square measure analyzed. From a global perspective, It also represents overall industry size by analyzing qualitative insights and historical data.

Key players operating in the global Healthcare Nanotechnology (Nanomedicine) market includes : Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith&Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International, and among others.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Healthcare Nanotechnology (Nanomedicine) Market @https://www.researchmoz.us/enquiry.php?type=S&repid2041239

Key Target Audience of the Healthcare Nanotechnology (Nanomedicine) market:

Scope of Healthcare Nanotechnology (Nanomedicine) Market:

The global Healthcare Nanotechnology (Nanomedicine) market is valued at million US$ in 2019 and will reach million US$ by the end of 2026, growing at a CAGR of during 2020-2026. The objectives of this study are to define, segment, and project the size of the Healthcare Nanotechnology (Nanomedicine) market based on company, product type, application and key regions.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Healthcare Nanotechnology (Nanomedicine) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Healthcare Nanotechnology (Nanomedicine) market.

The report offers an exhaustive geographical analysis of the global Healthcare Nanotechnology (Nanomedicine) market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The end users/applications and product categories analysis:

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate foreach application.

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid2041239

Healthcare Nanotechnology (Nanomedicine) Market The Regional analysis covers:

Key Findings & Data Available in Healthcare Nanotechnology (Nanomedicine) Market Report:

And Many More.

Get Discount on Healthcare Nanotechnology (Nanomedicine) Market Report :https://www.researchmoz.us/enquiry.php?type=D&repid2041239

Contact Us:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Follow us on LinkedIn @ http://bit.ly/2RtaFUo

Follow me on : https://marketnews-24.blogspot.com/

Read more:
Healthcare Nanotechnology (Nanomedicine) Market Analysis, Key Players, Industry Segments And Forecast To 2026 - The News Brok

Read More...

Global Nanotechnology Drug Delivery Market : Industry Analysis and Forecast (2019-2026): By Technology, Application and Region. – Good Night, Good…

Friday, August 21st, 2020

Global Nanotechnology Drug Delivery Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ 98.2 Bn by 2026, at a XX% CAGR of around during a forecast period.

Various novel technologies for developing effective drug delivery systems came into existence among which nanotechnology platforms for achieving targeted drug delivery are gaining prominence nowadays. Research in the medical field includes the development of drug nanoparticles, polymeric and inorganic biodegradable nano-carriers for drug delivery, and surface engineering of carrier molecules.

The report contains a detailed list of factors that will drive and restrain the growth of the Nanotechnology Drug Delivery Market. Such as, rapidly expanding areas of research and development to develop novel nano-medicine are expected to drive the nanotechnology drug delivery market growth in the future. Additionally, one of the major factors assisting market growth is the growing prevalence of infectious diseases and cancer, developing nanotechnology research, and increasing demand for novel drug delivery systems. However, high cost coupled with stringent regulatory scenario hinders the market growth to some extent.

Nanoparticles are expected to account for the largest XX% market share by 2026. The segment dominated the market as key nanoparticles like gold nanoparticles, dendrimers, and fullerenes are used in pharmaceutical drug delivery.The report offers a brief analysis of the major regions in the global nanotechnology drug delivery market, namely, APAC, Europe, North America, South America, and the Middle East & Africa. North America dominated the nanotechnology drug delivery market in 2018, because of high medical reimbursement facilities, and technological advancement. The APAC is projected to have the fastest growth, owing to a rapidly increasing population, an increase in consumer awareness, favorable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing economies such as China, and India in this region.

Nanotechnology drug delivery market report gives a competitive analysis of the individual standing of the companies against the global landscape of the medical industry. The forecast also provides the estimated trends in demand for the global market and their impact on the sizes of these companies to help the reader curate profitable business strategies. Such as Pfizer, Inc., AstraZeneca and Amgen signed agreements to collaborate with BIND Therapeutics to develop nano-medicines. These initiatives are expected to fuel the growth of the nanotechnology drug delivery market in the upcoming future.

The objective of the report is to present comprehensive analysis of Global Nanotechnology Drug Delivery Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Nanotechnology Drug Delivery Market dynamics, structure by analyzing the market segments, and project the Global Nanotechnology Drug Delivery Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Nanotechnology Drug Delivery Market make the report investors guide.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.Scope of the Global Nanotechnology Drug Delivery Market

Global Nanotechnology Drug Delivery Market, by Technology

Nanocrystals Nanoparticleso Dendrimerso Gold Nanoparticleso Dendrimerso Fullereneso Others Liposomes Micelles Nanotubes OthersGlobal Nanotechnology Drug Delivery Market, by Application

Neurology Oncology Cardiovascular/Physiology Anti-inflammatory/Immunology Anti-infective OthersGlobal Nanotechnology Drug Delivery Market, by Region

North America Asia Pacific Europe Middle East & Africa South AmericaKey players operating in the Global Nanotechnology Drug Delivery Market

Johnson & Johnson Merck & Co Roche Bayer Novartis Pharmaceuticals Pfizer AstraZeneca Amgen Celgene Corporation Angiotech Pharmaceuticals Capsulution Pharma AlphaRx Inc. Calando Pharmaceuticals Copernicus Therapeutics Elan Corporation Nanotherapeutics PAR Pharmaceutica Taiwan Liposome Co. AbbVie, Inc Amgen, Inc

Global Nanotechnology Drug Delivery Market Request For View Sample Report Page : @https://www.maximizemarketresearch.com/request-sample/39035About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:Name: Vikas GodageOrganization: MAXIMIZE MARKET RESEARCH PVT. LTD.Email: sales@maximizemarketresearch.comWebsite:www.maximizemarketresearch.com

See more here:
Global Nanotechnology Drug Delivery Market : Industry Analysis and Forecast (2019-2026): By Technology, Application and Region. - Good Night, Good...

Read More...

Page 6«..5678..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick